Imiquimod
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Basal Cell
Conditions
Carcinoma, Basal Cell
Trial Timeline
May 1, 2003 → Oct 1, 2007
NCT ID
NCT00189280About Imiquimod
Imiquimod is a phase 3 stage product being developed by Viatris for Carcinoma, Basal Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT00189280. Target conditions include Carcinoma, Basal Cell.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Basal Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189293 | Approved | Completed |
| NCT00189254 | Pre-clinical | Completed |
| NCT00189280 | Phase 3 | Completed |
| NCT00189241 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoma, Basal Cell